Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM0010 plus FOLFOX versus FOLFOX in second-line metastatic pancreatic cancer
2016-003858-33Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of ilodecakin in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PDAC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall survival. Started Jan 2017; status: completed.
02
Drugs
ilodecakin
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2016-003858-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003858-33.